Asymmetry Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Asymmetry Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-53,855	Closed	-$11.6M	–	35
2021 Q1	$11.6M	Buy	+53,855	New	+$11.8M	5.99%	4
2018 Q4	–	Sell	-12,650	Closed	-$2.44M	–	33
2018 Q3	$2.44M	Sell	12,650 -40,558	-76%	-$7.22M	2.25%	19
2018 Q2	$9.04M	Buy	+53,208	New	+$8.25M	8.89%	2

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Asymmetry Capital Management's VRTX Position: Q2 2021 in Review

Asymmetry Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 53,855 shares — an estimated $11.6M sold.

Asymmetry Capital Management first reported a position in VRTX in Q2 2018 and held it in 3 quarters. The position peaked at $11.6M in Q1 2021. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Asymmetry Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Asymmetry Capital Management sold 53,855 Vertex Pharmaceuticals shares in Q2 2021, an estimated $11.6M.
Asymmetry Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 3 quarters.
Asymmetry Capital Management's Vertex Pharmaceuticals position peaked at $11.6M in Q1 2021.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Asymmetry Capital Management's 13F filing for Q2 2021, filed 28 Jul 2021.